The co-mutational status of KRAS in NSCLC has been studied, showing that half (53%) of KRAS mt tumors had non-oncogenic co-mutations, the most frequent being TP53 (39%), serine/threonine kinase 11 (STK11) (20%), and kelch-like ECH-associated protein 1 (KEAP1) (13%), being probably clonal in nature and occurring early during oncogenesis (23–25). The gene discussed is TP53; the disease is non-small cell lung carcinoma.